AZAstraZeneca AZN · NYSE
$168.46 -0.22% (-$0.37)
- Market cap
- $261.3B
- Enterprise value
- $288.6B
- P/E
- 25.0x
- Forward P/E
- 16.5x
- PEG
- 0.6x
- P/S
- 4.3x
- P/FCF
- 29.9x
- EV/EBITDA
- 14.0x
- ROIC
- 12.8%
- Gross margin
- 81.9%
- Net margin
- 17.0%
- Dividend yield
- 1.92%
- Payout ratio
- 48.0%
- Net debt/EBITDA
- 1.3x
- Beta
- 0.21
- Free float
- 99.5%
About the company
AstraZeneca (AZN) is a British-Swedish pharmaceutical company specializing in the research, development, and production of drugs for a wide range of therapeutic areas, including oncology, cardiovascular, respiratory, and immunological diseases. The company is known for its emphasis on scientific innovation and global healthcare initiatives, enabling it to bring new treatment options to patients worldwide. AstraZeneca also invests in the development of biologics and personalized medicine to improve treatment efficacy and outcomes. AstraZeneca (AZN) shares could be suitable for investors looking for opportunities in the pharmaceutical sector with a focus on research, innovation, and a broad therapeutic portfolio.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Roland Soriot
Employees
96,100
Headquarters
Cambridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number